Wang K - Search Results

1

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.

Huo R, Li J, Li X, Shi J, Wang K, Jiao J, Shang Y. Huo R, et al. Among authors: wang k. Oncologist. 2020 Oct;25(10):826-832. doi: 10.1634/theoncologist.2019-0938. Epub 2020 Jun 11. Oncologist. 2020. PMID: 32367600 Free PMC article.

2

Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis.

Zhang X, Ran Y, Wang K, Zhu Y, Li J. Zhang X, et al. Among authors: wang k. Drug Des Devel Ther. 2016 Sep 28;10:3153-3161. doi: 10.2147/DDDT.S115493. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27729774 Free PMC article.

3

Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.

Shang Y, Li X, Liu W, Shi X, Yuan S, Huo R, Fang G, Han X, Zhang J, Wang K, Dou Z, Zhang Y, Zang A, Zhang L. Shang Y, et al. Among authors: wang k. Sci Rep. 2020 Nov 20;10(1):20243. doi: 10.1038/s41598-020-76791-y. Sci Rep. 2020. PMID: 33219256 Free PMC article.

4

Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.

Zhang X, Ran YG, Wang KJ. Zhang X, et al. Future Oncol. 2016 Dec;12(23):2741-2753. doi: 10.2217/fon-2016-0180. Epub 2016 Aug 15. Future Oncol. 2016. PMID: 27522860 Review.

5

Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.

Zhang X, Ran YG, Wang KJ. Zhang X, et al. Future Oncol. 2016 Jun;12(12):1529-39. doi: 10.2217/fon-2016-0020. Epub 2016 Apr 12. Future Oncol. 2016. PMID: 27067269

6

Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.

Zhang X, Shao Y, Wang K. Zhang X, et al. Among authors: wang k. Expert Rev Clin Pharmacol. 2016 Aug;9(8):1109-15. doi: 10.1080/17512433.2016.1190269. Epub 2016 Jun 1. Expert Rev Clin Pharmacol. 2016. PMID: 27181268 Review.

7

A HER2-mutant patient with late-stage duodenal adenocarcinoma benefited from anti-HER2 therapy and PD-1 inhibition: a case report.

Wang Z, Li W, Wei Y, An L, Su S, Xi C, Wang K, Hong D, Shi Y. Wang Z, et al. Among authors: wang k. J Gastrointest Oncol. 2021 Aug;12(4):1939-1943. doi: 10.21037/jgo-21-311. J Gastrointest Oncol. 2021. PMID: 34532140 Free PMC article.

8

SEMA3D Plays a Critical Role in Peptic Ulcer Disease-Related Carcinogenesis Induced by H. pylori Infection.

Wang Z, Wei Y, An L, Wang K, Hong D, Shi Y, Zang A, Su S, Li W. Wang Z, et al. Among authors: wang k. Int J Gen Med. 2022 Feb 9;15:1239-1260. doi: 10.2147/IJGM.S343635. eCollection 2022. Int J Gen Med. 2022. PMID: 35173464 Free PMC article.

9

Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.

Zhang X, Ran Y, Shao Y, Wang K, Zhu Y. Zhang X, et al. Among authors: wang k. Br J Clin Pharmacol. 2016 Jan;81(1):33-40. doi: 10.1111/bcp.12758. Epub 2015 Oct 30. Br J Clin Pharmacol. 2016. PMID: 26331893 Free PMC article. Review.

10

XRCC2 Arg188His polymorphism and colorectal cancer risk: a meta-analysis.

Wang Z, Wei Y, An L, Xi C, Wang K, Hong D, Shi Y, Zang A, Su S, Li W. Wang Z, et al. Among authors: wang k. J Int Med Res. 2021 Oct;49(10):3000605211039473. doi: 10.1177/03000605211039473. J Int Med Res. 2021. PMID: 34648414 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40,555 results

Search Page

Filters